[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovary-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovary-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,43,78,100,159,186,198,233,257,312,335,363,385,418,444,470,490,509,530,563,583,608],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053788","phase-2-an-evaluation-of-maintenance-therapy-combination-mirvetuximab-soravtansine-and-olaparib-100053788",false,"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib","A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer","Inclusion Criteria:\n\n* Provision to sign and date the consent form\n* Stated willingness to comply with all study procedures and be available for the duration of the study\n* Be a woman aged ≥18 years of age\n* Patients must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1\n* Patients must have a confirmed diagnosis of high-grade serous or endometrioid EOC, primary peritoneal cancer, or fallopian tube cancer\n* Patients must have platinum-sensitive disease defined as radiographic progression greater than 6 months from last dose of prior platinum therapy (not inclusive of current\u002Fmost recent platinum therapy)\n* Patients must have had documented complete or partial response, or stable disease, as defined by RECIST 1.1, from last line of platinum therapy\n* Patients must have available archival tissue block or slides to confirm FRalpha positivity\n* Patients' tumor must have FRalpha high or medium expression\n* Prior anticancer therapy:\n\n  * Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease.\n  * Most recent prior chemotherapy regimen must have consisted of at least 4 completed cycles and no more than 8 completed cycles\n  * Most recent prior chemotherapy regimen must have been platinum based\n  * Patients must have had testing for BRCA mutation (tumor or germline) and, if positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy\n  * Neoadjuvant +\u002F- adjuvant therapies are considered 1 line of therapy\n  * Maintenance therapy (eg, Bevacizumab, PARP inhibitors) will be considered part of preceding line of therapy (ie, not counted independently)\n  * Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)\n  * Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance\n  * Prior Bevacizumab use is allowed, but concurrent use with study combination is prohibited.\n  * Cycle 1 Day 1 of trial therapy must be within 8 weeks of last dose of previous chemotherapy.\n* Patients must have adequate hematologic, liver, and kidney function as defined as:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL (1500\u002FµL)\n  * Platelet count ≥ 100 x 109\u002FL (100,000 µL)\n  * Hemoglobin ≥ 10.0 g\u002FdL with no blood transfusion in the past 28 days\n  * Serum creatinine ≤ 1.5 x upper limit of normal (ULN)\n  * Patients must have creatinine clearance estimated of ≥51 mL\u002Fmin using the Cockcroft-Gault equation or based on a 24 hour urine test\n  * Aspartate aminotransferase (AST)(Serum Glutamic Oxaloacetic Transaminase (SGOT)) and alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x ULN unless liver metastases are present in which case they must be ≤ 5x ULN\n  * Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert syndrome are eligible if total bilirubin \\\u003C 3.0 x ULN)\n  * Serum albumin ≥ 2 g\u002FdL\n\nExclusion Criteria:\n\n* Patients with clear cell, mucinous, sarcomatous, low grade\u002Fborderline, germ cell, or sex-cord stromal type ovarian tumor\n* Patients who have progressed through most recent chemotherapy regimen. Stable disease (SD) is permissible.\n* Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment\n* Patients with active or chronic corneal disorders, history of corneal transplantation, or active ocular conditions require ongoing treatment\u002Fmonitoring, such as uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema, and\u002For monocular vision\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukemia or with features suggestive of MDS\u002FAML.\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to:\n\n  * Uncontrolled major seizure disorder\n  * Unstable spinal cord compression\n  * Any psychiatric disorder that prohibits obtaining informed consent.\n  * Active hepatitis B or C infection (whether or not on active antiviral therapy)\n  * Immunocompromised patients, e.g., patient who are known to be serologically positive for human immunodeficient virus(HIV)\n  * Active cytomegalovirus infection\n  * Any other concurrent infectious disease requiring IV antibiotics within 2 weeks prior to the first dose of MIRV\n* Patients with a history of multiple sclerosis (MS) or other demyelinating disease and\u002For Lambert-Eaton syndrome (paraneoplastic syndrome)\n* Patients with clinically significant cardiac disease including, but not limited to, any of the following\n\n  * Myocardial infarction ≤ 6 months prior to first dose\n  * Uncontrolled ventricular arrhythmia, recent (within 3 months)\n  * Superior vena cava syndrome\n  * Unstable angina pectoris\n  * Uncontrolled congestive heart failure (New York Heart Association \\> class II)\n  * Uncontrolled ≥ Grade 3 hypertension (per CTCAE)\n  * Uncontrolled cardiac arrhythmias\n* Patients with a history of hemorrhagic or ischemic stroke within 6 months prior to enrollment\n* Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)\n* Patients with a previous clinical diagnosis of noninfectious interstitial lung disease (ILD) or Extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan , including noninfectious pneumonitis\n* Persistent toxicities (\\>Common Terminology Criteria for Adverse Event (CTCAE) grade 2) caused by previous cancer therapy, excluding alopecia\n* Patients requiring use of folate-containing supplements (eg, folate deficiency)\n* Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.\n* Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.\n* Patients with prior hypersensitivity to monoclonal antibodies (mAb)\n* Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).\n* Women who are pregnant or breastfeeding, and who do not agree to use a highly effective contraceptive method(s) while on study drug and for at least 3 months after the last dose of MIRV and at least 6 months after the last dose of Olaparib. Females of childbearing potential must have a negative serum pregnancy test within 72 hours of study entry.\n* Patients who received prior treatment with MIRV or other FRα- targeting agents\n* Patients with duodenal stent or other GI disorder\u002Fdefect that would interfere with absorption of oral medication\n\n  * Includes patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication\n* Patients with known untreated or symptomatic central nervous system (CNS) metastases\n* Patients with a history of other malignancy within 3 years prior to enrollment\n\n  * Note: patients with tumors with a negligible risk for metastasis or death (eg, adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible\n* Prior known hypersensitivity reaction to study drugs and\u002For any of their excipients\n* Minor or major surgical procedure within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.\n* Inability to comply with study and follow-up procedures\n* Patients deemed otherwise clinically unfit for clinical trial per investigators discretion","FEMALE","18 Years","100 Years",{"count":20,"type":21},53,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.",[27,28,29],"Ovary Cancer","Peritoneal Cancer","Fallopian Tube Cancer","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2023-10-03",{"date":38,"type":21},"2031-01-31",{"name":40,"class":41},"University of Colorado, Denver","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100644592","integrating-systematic-patient-reported-evaluations-in-multi-disciplinary-tumor-boards-the-inspire-study-100644592","NCT07671937","INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study","INSPIRE","Inclusion\u002FExclusion Criteria: We will include two populations: (1) patients and (2) clinical team members involved in the MDTB.\n\nInclusion Criteria:\n\n* Inclusions Criteria- Patients:\n\n  1. aged 18 years or older;\n  2. with suspected or confirmed diagnosis of pancreatic, breast, and gynecologic cancer (all stages) within 8 weeks of diagnosis;\n  3. intention to be treated at a participating institution;\n  4. with verbal fluency in English or Spanish; and\n  5. scheduled to be discussed at MDTB.\n* Inclusion criteria - Clinicians:\n\nAll clinical team members participating in the pancreatic, breast, or gynecologic MDTB at a participating site will be included and have pre-emptively agreed to participation.\n\nExclusion Criteria:\n\n* Exclusion criteria - Patients:\n\nIndividuals with plans to receive cancer treatment outside the participating institution and inability to speak English or Spanish.\n\n* Exclusion criteria - Clinician:\n\nClinicians will retain the opportunity to opt-out of participation, in which case their portions of the discussion will not be included in the analysis; however, this is not anticipated based on pilot data.","ALL",{"count":52,"type":21},2748,[54],"NA","The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves including electronic patient reported outcomes (ePROs) within MDTB on MDTB discussion content, provider burden, treatment recommended and received, healthcare utilization, and patient-reported outcomes.",[57,58,27,59,60],"Breast Cancer","Corpus Uteri Cancer","Pancreas Cancer","Other Female Genital Malignant Neoplasms",[62,63,64,65,57,66],"PROs","Multidiscipinary tumor board","INSPIRE intervention","Pancreatic Cancer","gynecologic cancers","NOT_YET_RECRUITING","2026-06-30",{"date":70,"type":34},"2026-07-02",{"date":72,"type":21},"2026-09-01",{"date":74,"type":21},"2031-07",{"name":76,"class":41},"University of Alabama at Birmingham",3,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100643907","phase-2-an-exploratory-study-on-the-use-of-ipalotinib-tislelizumab-combined-with-sunitinib-and-olaparib-for-neoadjuvant-therapy-in-hrd-positive-advanced-ovarian-cancer-100643907","NCT07667751","An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Female participants aged ≥18 years and ≤75 years at enrollment;\n2. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma, with histopathological confirmation of high-grade serous carcinoma or endometrioid carcinoma, and FIGO stage (2014 edition) III-IV;\n3. Meeting the neoadjuvant indications for ovarian cancer (preoperative evaluation by a gynecologic oncologist indicates low likelihood of achieving R0 resection with initial debulking surgery, or the patient's physical condition is unsuitable for immediate surgery due to poor tolerance to PDS);\n4. Positive HRD testing result;\n5. Presence of at least one measurable lesion meeting RECIST 1.1 criteria;\n6. Expected survival time ≥12 weeks;\n7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n8. Absence of severe hematologic, cardiac, pulmonary, hepatic, renal dysfunction, or immunodeficiency disorders. Within one week prior to the first administration, the functional status of vital organs must meet the following requirements (supportive therapies such as any blood components or cell growth factors are prohibited within 14 days before the first dose):\n\n   1. Complete blood count: HGB ≥ 90 g\u002FL; WBC ≥ 4.0 × 10⁹\u002FL; NEUT ≥ 2.0 × 10⁹\u002FL; PLT ≥ 100 × 10⁹\u002FL;\n   2. Blood biochemistry: TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN with creatinine clearance ≥ 50 mL\u002Fmin;\n   3. Coagulation function: INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN;\n   4. Within 4 weeks prior to the first dose, cardiac ultrasound must demonstrate: left ventricular ejection fraction (LVEF)\\> 50%;\n9. Pregnancy test results must be negative in patients of childbearing age, with voluntary use of effective and reliable contraceptive measures during the study;\n10. Participants must voluntarily enroll in the study, sign an informed consent form, demonstrate good compliance, and agree to participate in follow-up visits.\n\nExclusion Criteria:\n\n1. Ovarian cancer, fallopian tube cancer, primary peritoneal cancer (e.g., germ cell tumors), or ovarian tumors with low malignant potential (e.g., borderline tumors) of non-epithelial origin;\n2. Previous receipt of antitumor therapy, including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy (Note: lymph node dissection or biopsy performed for clinical staging purposes using tissue obtained via puncture biopsy or laparoscopic exploration is permitted);\n3. History of other malignancies within the past 5 years, excluding cured localized tumors (e.g., basal cell carcinoma of skin, squamous cell carcinoma of skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ);\n4. Participation in other drug clinical trials and use of investigational drugs within 4 weeks prior to enrollment;\n5. Administration of live attenuated vaccines within 4 weeks before initial dosing or planned during the study period;\n6. Known history of allergy to any component of this regimen;\n7. Subjects with active infectious diseases;\n8. Subjects with any severe and\u002For uncontrolled diseases;\n9. Active autoimmune diseases requiring systemic treatment within 2 years prior to study initiation, or autoimmune diseases at risk of recurrence; exceptions include: non-systemically treatable dermatoses (e.g., vitiligo, alopecia, psoriasis, or eczema); hypothyroidism due to autoimmune thyroiditis requiring only stable hormone replacement therapy; well-controlled type 1 diabetes mellitus; and conditions deemed by investigators unlikely to recur without external triggers;\n10. Pregnant or breastfeeding women, or women of childbearing potential with positive baseline pregnancy test results.\n11. According to the investigator's assessment, the patient has a severe comorbid condition that poses significant risks to safety or impedes participation in the study, including but not limited to: severe hypertension uncontrolled by medication (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg), myocardial ischemia or myocardial infarction, severe arrhythmias, congestive heart failure grade ≥2, severe pulmonary dysfunction\u002Fdisease, severe diabetes mellitus, or active infections;\n12. A documented history of neurological or psychiatric disorders, including epilepsy or dementia;\n13. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n14. Known history of interstitial lung disease or non-infectious pneumonia;\n15. Diagnosis of immunodeficiency or ongoing systemic glucocorticoid therapy or any other form of immunosuppressive treatment;\n16. Presence of any condition increasing bleeding risk, such as severe hemorrhoids, acute gastritis, or gastric and duodenal ulcers;\n17. History of dysphagia or any gastrointestinal disorder affecting drug absorption;\n18. Any other circumstances deemed inappropriate for study participation by the investigator.","75 Years",{"count":86,"type":21},35,[24],"The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs. Tyrosine kinase inhibitors (TKIs) can induce immune microenvironment remodeling and exhibit synergistic effects with immune checkpoint inhibitors. To further evaluate the efficacy and safety of epalolide combined with torvolumab plus sunitinib and olaparib as neoadjuvant therapy in HRD-positive untreated patients with advanced ovarian cancer, a prospective, multicenter, single-arm exploratory study is proposed. This study will enroll 35 untreated HRD-positive advanced ovarian cancer patients who will receive neoadjuvant treatment with epalolide plus torvolumab combined with sunitinib and olaparib. Patients achieving CR\u002FPR\u002FSD after neoadjuvant therapy will undergo intermediate tumor cytoreductive surgery, followed by 6 cycles of adjuvant chemotherapy and 1 year of maintenance therapy with the etoricoxib-drug combination antibody regimen. The primary endpoint is R0 resection rate, aiming to provide valuable insights into neoadjuvant treatment strategies for advanced ovarian cancer patients.",[27],"2026-06-19",{"date":92,"type":34},"2026-06-25",{"date":94,"type":34},"2026-06-01",{"date":96,"type":21},"2027-12-31",{"name":98,"class":41},"Bai-Rong Xia",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":132,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":109,"type":21},474,[111,24],"PHASE1","The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[114,115,116,117,118,119,59,120,121,122,123,124,125,126,127,128,129,27,130,131],"Solid Tumor, Adult","Colorectal Cancer","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Colon Cancer","Rectal Cancer","Cancer","Ovarian Cancer","Ovarian Neoplasms","Mesothelioma","Mesothelioma, Malignant","Lung Cancer","MESOM",[133,134,135,136,137,138,139,140,141,142,143,144,125,145,122,115,130,116,146,131,126,128,147],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate","2026-06-10",{"date":150,"type":34},"2026-06-12",{"date":152,"type":34},"2024-04-03",{"date":154,"type":21},"2029-06",{"name":156,"class":157},"A2 Biotherapeutics Inc.","INDUSTRY",12,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":77},"100470233","marathon-of-hope-cancer-centres-network-study-for-ontario-mohccn-o-100470233","NCT05403177","Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)","MOHCCN-O","Inclusion Criteria:\n\n1. Patients with histological and\u002For cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy\n2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:\n\n   1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)\n   2. Have sufficient biospecimens (tumor and\u002For blood samples) available for more comprehensive molecular and immunophenotypic characterization\n3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.\n4. Participating patients must agree to share their anonymized clinical and genomic data\n\nExclusion Criteria:\n\nNone.",{"count":167,"type":21},500,"OBSERVATIONAL","The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients",[57,115,59,171,172,27,173,174,175,130,176,177],"Kidney Cancer","Prostate Cancer","Head and Neck Cancer","Leukemia","Lymphoma","Melanoma","Solid Tumor","2026-06-09",{"date":148,"type":34},{"date":181,"type":34},"2022-06-23",{"date":183,"type":21},"2030-10",{"name":185,"class":41},"University Health Network, Toronto",{"id":187,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":25,"conditions":190,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":195,"leadSponsor":196,"locationsCount":197},"100507455",{"count":20,"type":21},[24],[27,28,29],"2026-06-02",{"date":193,"type":34},"2026-06-04",{"date":36,"type":34},{"date":38,"type":21},{"name":40,"class":41},5,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":205,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":217,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":99},"100496383","physical-activity-intervention-among-older-women-with-gynecologic-cancers-fit4treatment-100496383","NCT05743517","Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)","Patient-Tailored Physical Activity Intervention Among Older Women With Gynecologic Cancers Undergoing Chemotherapy (Fit4Treatment)","Inclusion Criteria:\n\n* Female; \\> 60 years of age\n* Diagnosis of endometrial\u002Futerine, ovarian, cervical or vulvar\u002Fvaginal cancer\n* Undergoing or planning to undergo any systemic treatment for a gynecologic malignancy (e.g., chemotherapy, immunotherapy, anti-angiogenic therapies, targeted therapies, etc.)\n* Willing to try to identify an exercise partner to participate with them, if needed\n* Fluent in English\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular disease or other major contraindications to physical activity\n* Active brain metastases\n* Cognitive or functional limitations that preclude a patient's ability to participate in the physical activity intervention\n* Pregnant women or prisoners","60 Years",{"count":207,"type":21},192,[54],"The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core intervention of a wearable activity tracker and commercially available app, will improve physical activity. The findings will generate meaningful knowledge about how to best increase physical activity in older gynecologic cancer patients receiving systemic cancer therapies to improve quality of life and cancer-specific survival.",[27,211,212,213,214,215,216],"Endometrial Cancer","Uterine Cancer","Cervical Cancer","Cervix Cancer","Vulvar Cancer","Vaginal Cancer",[218,219,220,221,222,223],"behavioral intervention","physical activity","cancer outcomes","chemotherapy","systemic therapy","quality of life","2026-05-27",{"date":226,"type":34},"2026-05-29",{"date":228,"type":34},"2023-09-15",{"date":230,"type":21},"2029-08-01",{"name":232,"class":41},"Northwestern University",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":99},"100515355","alternate-day-fasting-after-surgery-for-patients-undergoing-chemotherapy-100515355","NCT05990426","Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy","The Impact of Alternate Day Fasting After Surgery for Patients Undergoing chemoTherapy (FAST Study)","FAST","Inclusion Criteria:\n\n1. Female; ≥ 18 years of age\n2. Confirmed or high suspicion for endometrial, ovarian, fallopian tube or primary peritoneal cancer, and are able and expecting to undergo adjuvant chemotherapy following hysterectomy for treatment of disease, as determined by their treating physician\n3. Fluent in spoken and written English\n4. Own a smart phone\n5. Have access to the internet to complete surveys\n6. ECOG status of 0 or 1\n7. Willingness to sign informed consent form\n\nExclusion Criteria:\n\n1. Patients who are not planning to undergo chemotherapy at Northwestern Medicine\n2. Patients engaged in shift work (i.e., those who work nights, 3rd shift)\n3. BMI of 50+ or those with a diagnosed eating disorder. Patients who take medications for blood glucose regulation (e.g. insulin), and\u002For require treatment with therapeutic doses of anticoagulants will be excluded.\n4. Patients who have been diagnosed with medication-dependent diabetes, recent myocardial infarction, stroke, pulmonary embolus, renal failure, or any condition that may preclude ability to tolerate a short-term fast will be excluded.\n5. Patients who take medications where conditions may be influenced in the presence of fasting (e.g. hypertension, electrolyte abnormalities, migraines) will be monitored by their treating physician for any necessary adjustments in these medications.\n6. Patients whose oncologist has not provided clearance for their participation\n7. Unable or unwilling to follow a diet regimen or participate in ketone measurements\n8. ECOG status greater than 1\n9. Patients who have undergone prior systemic therapy to treat a malignancy in the last 2 years.",{"count":242,"type":21},30,[54],"Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously shown to be safe. There is no data specifically addressing the impact of a fasting diet regimen on side effects of chemotherapy during treatment for ovarian and endometrial cancers in the front-line setting. The information gathered from this study will inform future trials about the role of time-restricted eating and its impact on side-effects associated with chemotherapy as well as its role in improvement of quality of life for women afflicted with these debilitating diseases.",[27,211,212],[221,247,248],"peripheral neuropathy","intermittent fasting","2026-03-20",{"date":251,"type":34},"2026-03-24",{"date":253,"type":34},"2023-10-16",{"date":255,"type":21},"2026-08",{"name":232,"class":41},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":99},"100536733","phase-2-tart-cherry-juice-as-a-dietary-supplement-for-the-prevention-of-paclitaxel-induced-neuropathy-100536733","NCT06268665","Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","A Randomized Trial of Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy","Inclusion Criteria:\n\n* Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.\n* Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.\n\n  * Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.\n  * Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.\n  * Concurrent use of immune checkpoint inhibitor therapy is allowed.\n  * (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed.\n  * Concurrent use of carboplatin with weekly paclitaxel in the study is allowed.\n* May participate concurrently in other cancer trials.\n* Must be able to complete questionnaires in English or Spanish.\n* Age ≥ 18 years old at the time of consent.\n* ECOG performance status of 0 - 1 (Karnofsky scale ≥ 70%, see Appendix).\n* Ability to understand and the willingness to sign a written informed consent document.\n* Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation).\n* Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART)\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\n  * A CD4 count above 250 cells\u002FµL and an undetectable HIV viral load on standard PCR-based tests within the last year.\n* Stated willingness to not drink any additional tart cherry or any cherry juice while on the study.\n* Ability and willingness to adhere to the study visit schedule and other protocol requirements\n\nExclusion Criteria:\n\n* Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (≥ 2 week washout period required).\n* Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus.\n* Currently taking anticoagulant medication.\n* Currently taking Vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements\u002Fmedications, they must agree to stop at the time of registration. Multivitamins containing Vitamin E are allowed, however Vitamin E \\> 1,000 international units (IU) must be discontinued at the time of registration.\n* Patients may not use cold therapy gloves for chemotherapy induced neuropathy.\n* Known allergy to cherries.\n* Inability to swallow liquid.\n* Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation).\n* Any condition that would prohibit the understanding or rendering of informed consent.\n* Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial.",{"count":265,"type":21},86,[24],"This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy.\n\nEligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).",[57,269,270,271,272,273,126,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,27,302],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III","Breast Cancer Stage IV","Invasive Breast Cancer","Ovarian Cancer Stage 1","Ovarian Cancer Stage II","Ovarian Cancer Stage III","Ovarian Cancer Stage IV","Ovarian Cancer Stage IA","Ovarian Cancer Stage IB","Ovarian Cancer Stage IC","Ovarian Cancer Stage 2","Ovarian Cancer Stage 3","Ovarian Cancer Stage IIIb","Ovarian Cancer Stage IIIC","Breast Cancer Stage IIIA","Breast Cancer Invasive","Breast Cancer, Stage IA","Breast Cancer, Stage IB","Breast Cancer Stage IIA","Breast Cancer Stage IIB","Breast Cancer Stage IIIB","Breast Cancer Stage IIIc","Cancer, Breast","Tumors, Breast","Mammary Cancer","Mammary Carcinoma","Breast Carcinoma","Breast Neoplasm","Malignant Breast Neoplasm","Malignant Tumor of Breast","Cancer of Ovary","Ovary Neoplasm","2026-03-02",{"date":305,"type":34},"2026-03-04",{"date":307,"type":34},"2024-08-15",{"date":309,"type":21},"2027-12",{"name":311,"class":41},"University of California, Davis",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":99},"100599413","multimedia-aid-for-genetic-testing-in-gynecologic-oncology-100599413","NCT07084168","Multimedia Aid for Genetic Testing in Gynecologic Oncology","Inclusion Criteria:\n\nIn order to participate in this study, a subject must meet all of the eligibility criteria outlined below.\n\n* Reviewed informed consent to participate in the study.\n* Subject is willing and able to comply with study procedures based on the judgment of the investigator.\n* Age ≥ 18 years at the time of consent.\n* Diagnosis of ovarian cancer or endometrial cancer\n* Eligible for genetic testing\n* English or Spanish is the primary language\n\nExclusion Criteria:\n\n* Previously completed genetic testing\n* Did not receive initial cancer-directed treatment at study site",{"count":242,"type":21},[54],"This pilot study aims to estimate rates of genetic testing in patients with ovarian and endometrial cancer before and after the implementation of educational videos about genetic testing. Subjects will be asked to view one of three videos relevant to their cancer diagnosis and genetic testing, and have the option to complete a brief satisfaction survey. A chart review to evaluate rates of genetic testing ordered and referrals placed to Genetics before and after the implementation of the videos will be conducted.\n\nUp to 15-20% of ovarian cancer and 3-5% of endometrial cancer is due to inherited genetic mutation. Given this association, the National Comprehensive Cancer Network (NCCN) recommends genetic counseling and testing for all individuals with a diagnosis of ovarian cancer and endometrial cancer. Some challenges to obtaining genetic counseling and testing include missed identification and referral of eligible patients by providers, lack of provider knowledge, and busy clinic visits limiting time for informed consent and maintaining patient autonomy for genetic testing. Although heterogeneous, the literature supports multimedia use in cancer genetics. However, there is a paucity of data in the field of gynecologic oncology for the role of integrating a multimedia approach to genetic counseling.",[27,211],[323,324,325],"genetic testing","video implementation","chart review","2025-11-10",{"date":328,"type":34},"2025-11-12",{"date":330,"type":34},"2024-10-10",{"date":332,"type":21},"2026-10-30",{"name":334,"class":41},"UNC Lineberger Comprehensive Cancer Center",{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":362},"100563573","phase-2-study-of-senaparib-in-combination-with-temozolomide-in-arid1a-mutation-associated-ovarian-cancer-100563573","NCT06617923","Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer","A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n* Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal carcinoma. Histologic documentation (via the pathology report) indicating at least 50% endometrioid or clear cell morphology is required.\n* Presence of an ARID1A pathologic variant or likely pathogenic variant identified by next generation sequencing (NGS) tests (per criteria below)\n\n  * Pathogenic or likely pathogenic ARID1A variant identified NGS tests performed by the labs listed on https:\u002F\u002Fecog-acrin.org\u002Fnci-match-eay131-designated-labs will be considered confirmed for the purposes of this study.\n  * Pathogenic ARID1A mutation identified by other NGS tests will need to be confirmed by the study PI prior to enrollment.\n* All patients must have measurable disease, according to RECIST v1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. To be considered pathologically enlarged and measurable, a lymph node must be ≥15 mm in short axis when assessed by CT scan or MRI (CT scan slice thickness recommended to be no greater than 5 mm). See Section 12 for the evaluation of measurable disease.\n\n  * Patients who have received radiation must have evidence of measurable disease outside of the radiation field or have documented progression after radiation at the time of enrollment.\n* Patients must have received at least two prior cytotoxic regimens or have platinum-resistant (defined as having progressed within 6 months of last platinum therapy) or platinum-refractory (having progressed during primary platinum therapy) disease.\n\n  * Participants can have received no more than 3 prior lines of cytotoxic therapy (any agent that targets the genetic and\u002For mitotic apparatus of dividing cells, resulting in dose-limiting toxicity to the bone marrow).\n  * Unlimited prior hormonal therapy, targeted therapy (including immunotherapy) or antiangiogenic therapy will be permitted.\n* Patients must have completed prior therapy as detailed below:\n\n  * Prior Therapy Time from last prior therapy to study treatment start date Chemotherapy (except nitrosoureas or mitomycin C) ≥ 28 days; Nitrosoureas or mitomycin C ≥ 42 days; Small molecule inhibitors ≥ 28 days; Monoclonal antibodies ≥ 28 days; Immunotherapy ≥ 28 days; Radiotherapy (RT) ≥ 28 days from last local site RT ≥ 28 days from stereotactic radiosurgery; ≥ 12 weeks from craniospinal ≥50% radiation of pelvis or total body irradiation Radiation related side effects must have resolved prior to study enrollment Endocrine therapy ≥ 7 days\n* Ability to take oral medications and not have gastrointestinal illnesses that would preclude absorption of senaparib or TMZ as judged by the treating physician.\n* Patients assigned female at birth, age ≥18 years. Because no dosing or adverse event data are currently available on the use of senaparib and TMZ in patients \\\u003C18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%, see Appendix A).\n* Patients must have adequate organ and marrow function as defined below:\n\n  * Absolute Neutrophil Count ≥1,000\u002Fmicroliter (mcL);\n  * Differential Differential with no clinically significant morphologic abnormalities on complete blood count (CBC) testing.\n  * Manual differential is encouraged, if clinically indicated, and in cases where an automated differential is abnormal.\n  * Hemoglobin ≥9 g\u002FdL;\n  * Platelets ≥100,000\u002FmcL;\n  * aspartate transferase (AST) (SGOT) or Alanine Transaminase (ALT) (SGPT) ≤3 × institutional ULN;\n  * Total Bilirubin ≤1.5 × institutional ULN; Direct bilirubin ≤ ULN for subjects with total bilirubin \\> 1.5 x ULN (patients with isolated indirect bilirubin elevations and a history of Gilbert's Syndrome are eligible)\n  * Creatinine -OR- Glomerular Filtration Rate ≤ institutional upper limit normal (ULN) -OR- ≥50 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional ULN\n* Because of the potential DNA damaging effects in a developing human fetus with the study treatment, participants of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation including for one month after last dose of senaparib or temozolomide. Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately. Theoretically, CYP3A induction with senaparib use may result in the loss of efficacy in hormonal contraceptives, thus a barrier method of contraception must be used in addition to hormonal contraceptives due to the potential drug-drug interaction with senaparib. Note: All females will be considered to be of childbearing potential unless postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (ie, bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).\n* For patients with known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated and the suppressive therapy must not be an excluded concurrent medication.\n* Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the patients are eligible if the patient has an undetectable HCV viral load and the HCV therapy is not an excluded concurrent medication.\n* Patients with treated brain metastases are eligible if follow-up brain imaging ≥ 12 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial, with permission of the protocol chair.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n\nExclusion Criteria:\n\n* Prior treatment with a poly ADP ribose polymerase (PARP) inhibitor or temozolomide.\n* Patients who are currently receiving or have previously received any other investigational agents within 3 weeks prior to entering the study.\n* Patients who have not recovered (CTCAE v5 grade ≤1) from adverse events due to agents administered more than 4 weeks earlier, unless those events are deemed to have returned to baseline, are irreversible, or are unlikely to develop into a life-threatening condition at the permission of the Protocol Chair (e.g., alopecia).\n* Patients who have any of the following:\n\n  * A prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).\n  * Abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and myeloproliferative neoplasms (MPN) (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing.\n  * A prior history of T-cell lymphoblastic lymphoma\u002Flymphoblastic leukemia (T-ALL).\n* Patients with clinical or radiographic evidence of bowel obstruction.\n* Severe, active comorbidity per the treating investigator's clinical discretion.\n* Pregnant or lactating patients.\n* Patients with known human immunodeficiency virus (HIV) infection are ineligible because the treatments involved in this protocol may be immunosuppressive, increasing the risk of lethal infections in this patient population.\n* Patients with known, untreated brain metastases, as progressive neurologic dysfunction may develop that would confound the evaluation of neurologic and other adverse events.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to senaparib or temozolomide.\n* Strong CYP3A4 inhibitors or inducers should not be used within 3 days of Day 1 dosing until the end of study. Moderate CYP3A4 inhibitors or inducers should be used with caution.\n\nBecause the lists of these agents are constantly changing, it is important to regularly consult a frequently updated list such as http:\u002F\u002Fmedicine.iupui.edu\u002F clinpharm\u002Fddis\u002Ftable.aspx; medical reference texts such as the Physicians' Desk Reference may also provide this information. As part of the enrollment\u002Finformed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product.\n\n* Uncontrolled intercurrent illness including, but not limited to, the following:\n\n  * ongoing or active infection, including latent tuberculosis infection,\n  * clinically significant GI disease (such as active Crohn's disease or ulcerative colitis),\n  * recent or significant cardiovascular disease (defined as any major CV event within the previous 6 months including myocardial infarction, unstable angina, cardiac arrhythmia, stroke, Pulmonary Embolism (PE), or New York Heart Association Class III or IV heart failure),\n  * history of liver function abnormality requiring investigation, drug induced liver injury, chronic liver disease, excessive alcohol consumption or chronic alcohol-induced disease,\n  * psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, or\n  * any other severe acute or chronic medical condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects of senaparib and temozolomide. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study. These potential risks may also apply to other agents used in this study.",{"count":343,"type":21},18,[24],"This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.",[27,29,347],"Primary Peritoneal Cavity Cancer",[349,350,351,352],"ovarian","endometrioid","clear cell","ARID1A mutation","2025-10-24",{"date":355,"type":34},"2025-10-27",{"date":357,"type":34},"2025-02-06",{"date":359,"type":21},"2029-12",{"name":361,"class":41},"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",2,{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":22,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":99},"100609331","no-stoma-policy-in-advanced-ovarian-cancer-surgery-100609331","NCT07213193","No-Stoma Policy in Advanced Ovarian Cancer Surgery","No-Stoma Policy in Advanced Ovarian Cancer Surgery, Feasibility and Outcomes","No-Stoma","Inclusion Criteria:\n\n* Patients with suspected or anatomopathological diagnosis of malignant ovarian tumor undergoing elective primary or secondary cytoreduction and needing rectosigmoid resection and anastomosis\n* Informed consent signed prior to performing any procedure related to the clinical trial\n* Age 18 years old.\n\nExclusion Criteria:\n\n* Patients with histologies other than ovarian tumor.\n* Only palliative surgery planned\n* Patients who do not require sigmoid-rectum resection after intraoperative evaluation\n* Patients who do not receive colorectal anastomosis and undergo end ostomy",{"count":372,"type":21},395,[54],"Resection of the sigmoid-rectum is a procedure frequently required in cytoreductive surgery for advanced ovarian cancer, and it is also among the procedures with the highest risk of complications. One of the major, albeit uncommon, complications of intestinal anastomosis is anastomotic leakage. According to the literature, the rate of anastomotic leakage following cytoreductive surgery for ovarian cancer ranges from 1.7% to 17%.\n\nThe risk factors associated with this complication are varied and often inconsistent across studies. They range from preoperative clinical conditions-such as age, low albumin levels, and Body Mass Index \\\u003C 18-to intraoperative factors such as low to mid rectal resection, high ligation of the inferior mesenteric artery, and multiple bowel resections.\n\nApart from the rehabilitative programs introduced by the Enhanced Recovery After Surgery protocol-which aim to improve the nutritional status of patients undergoing cytoreductive surgery for ovarian cancer-we currently lack validated tools to reduce the risk of leakage. The most commonly used strategy remains the creation of a protective stoma. However, several studies have shown that this procedure is not actually a protective factor against anastomotic leakage; rather, its utility lies in mitigating the severity of the complication.\n\nNonetheless, stomas have a significant clinical and psychological impact, with complication rates ranging from 33.9% to 45% and reversal rates between 66.5% and 89%.\n\nThis study aims to evaluate the feasibility of a no-stoma strategy in a selected \"low-risk\" population for anastomotic leakage among patients undergoing cytoreductive surgery for primary or recurrent ovarian cancer. Focusing on the goal of achieving a zero stoma rate, the study will provide valuable insights into the utility and outcomes of stoma creation. The results will support more informed and patient-centered clinical decisions in the management of ovarian cancer.",[27],"2025-10-01",{"date":378,"type":34},"2025-10-08",{"date":380,"type":34},"2025-05-01",{"date":382,"type":21},"2028-12-20",{"name":384,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":394,"briefSummary":395,"conditions":396,"keywords":404,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":99},"100462046","phase-1-anti-ny-eso-1-tcr-gene-engineered-lymphocytes-given-by-infusion-to-patients-with-ny-eso-1--expressing-metastatic-cancers-100462046","NCT05296564","Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","A Phase I\u002FII Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","Inclusion Criteria:\n\n1. Have histologically or cytologically confirmed diagnosis of neoplasia\n2. Measurable (per RECIST v1.1 criteria) metastatic cancer or locally advanced refractory\u002Frecurrent malignancy not amenable to curative treatment. Lesions previously irradiated may be considered measurable only if growth has been documented since local treatment completion.\n3. The tumor expresses ESO as assessed immunohistochemistry of resected tissue. To this end, archived tumor tissue suitable for analysis must be available or re-biopsy performed on study. Tissue staining must encompass more than 10% of tumor section.\n4. Patients must have previously either (1) received at least first-line or second-line standard therapy for metastatic disease, if known to be effective for that disease, and have been either non-responders (progressive disease), intolerable or have recurred or (2) Recurred within 6 months of adjuvant systemic therapy known to be active also in the metastatic setting.\n5. Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for 1 month after treatment for the patient to be eligible. Patients with surgically resected brain metastases are eligible.\n6. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).\n7. Age ≥ 18 years and ≤ 70 years.\n8. Patient is able to understand and willing to sign a written informed consent.\n9. Clinical performance status of ECOG 0, 1 or 2.\n10. HLA-A\\*0201or A\\*0206 positive.\n11. Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatment.\n12. Women of child-bearing potential must have a negative pregnancy test.\n13. Serology: Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n14. Hematology\n\n    * ANC \\> 1500\u002Fmm3 without the support of filgrastim\n    * WBC ≥ 3000\u002Fmm3\n    * Platelet count ≥ 100,000\u002Fmm3\n    * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n15. Chemistry\n\n    * Serum ALT\u002FAST ≤ 2.5 x ULN\n    * Creatinine clearance ≥40ml\u002Fmin\n    * Total bilirubin ≤ 1.5 mg\u002FdL, except in patients with Gilbert's Syndrome, who must have a total bilirubin \\\u003C 3.0 mg\u002FdL.\n    * INR \\\u003C 1.5\n\nExclusion Criteria:\n\n1. Women of child-bearing potential who are pregnant or breastfeeding.\n2. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n3. Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses\n4. Concurrent systemic steroid therapy, not including replacement therapy or treatment with prednisone up to 10mg daily or its equivalent. Or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention.\n5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n6. Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within 3 months.\n7. Subjects unable to maintain normal oxygen saturation level in room air.\n8. Subjects who have had a venous thromboembolic event requiring anticoagulation and who meet any of the following criteria:\n\n   * Have been on a stable dose of anticoagulation for \\\u003C 1 month (except for acute line insertion induced thrombosis).\n   * Have had a Grade 2, 3, or 4 hemorrhage in the last 30 days or are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement).\n9. Has a known additional malignancy within the last 3 years. Exceptions include early stage cancers (carcinoma in situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy).\n10. LVEF ≤ 40%\n11. Documented FEV1 ≤ 60% predicted tested in patients with:\n\n    * A prolonged history of cigarette smoking (≥ 20 pack-year smoking history, with cessation within the past two years).\n    * Symptoms of respiratory dysfunction.\n12. Patients who are at the time of study initiation receiving any other investigational agents.\n13. Carcinomatosis meningitis or other brain involvement exceeding that allowed above.\n14. Has received live vaccine within 30 days before the first dose of study intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.","70 Years",{"count":77,"type":21},[111,24],"A Phase I\u002FII Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers",[397,398,399,400,401,117,402,403,27],"Sarcoma, Synovial","Sarcoma,Soft Tissue","Melanoma Stage IV","Triple Negative Breast Cancer","Metastatic Cancer","Bladder Urothelial Carcinoma","Neuroblastoma, Metastatic",[405,406,407,408],"NY-ESO-1","TCR","adoptive transfer","retroviral transduction","2025-09-29",{"date":411,"type":34},"2025-10-02",{"date":413,"type":34},"2022-04-01",{"date":415,"type":21},"2027-12-30",{"name":417,"class":41},"Hadassah Medical Organization",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":99},"100598205","phase-3-icra-randomised-controlled-trial-100598205","NCT07068464","ICRA Randomised Controlled Trial","Overall Survival Following Interval and Delayed Cytoreduction Surgery in Advanced Stage Ovarian Cancer: a Pragmatic Phase III Randomised Controlled Trial","ICRA","Inclusion Criteria:\n\n1. Women ≥18 years of age.\n2. Histologically confirmed high grade, serous, or endometrioid ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma.\n3. International Federation of Gynecologic Oncology (FIGO) 2014 stage IIIA-IVB unsuitable for complete primary cytoreductive surgery because disease unresectable. Assessment of unresectable disease must have been made by staging CT chest abdomen pelvis +\u002F- diagnostic laparoscopy.\n4. Disease must be deemed resectable after three courses of neoadjuvant chemotherapy.\n5. Patient must be fit for cytoreduction surgery and chemotherapy.\n\nExclusion Criteria:\n\n1. Women undergoing primary and recurrent cytoreductive surgery.\n2. Mucinous, clear cell, carcinosarcoma, low-grade serous carcinoma, germ cell and sex cord stromal histopathologies.\n3. Synchronous malignancies.\n4. Unfit for surgery and or chemotherapy.\n5. Pregnant or breastfeeding women.\n6. Delivery of HIPEC at cytoreduction surgery.",{"count":427,"type":21},682,[429],"PHASE3","The standard of care for advanced stage epithelial ovarian cancer is primary cytoreduction surgery with the aim of complete cytoreduction, followed by platinum and taxane-based chemotherapy and consideration of maintenance therapy (bevacizumab or Poly ADP-ribose polymerase (PARP)-inhibitor). Neoadjuvant chemotherapy before and after interval cytoreduction surgery has become an alternative approach as randomized controlled trials have demonstrated non-inferiority of this type of management over primary surgery. In these studies, neoadjuvant chemotherapy was restricted to three to four cycles. However, real-world clinical practice varies, with centres giving more than four pre-operative cycles. The decision to delay surgery is complex and influenced by multiple factors. These include poor performance status, radiological evidence of unresectable sites of disease, or insufficient surgical resources (either lack of surgical expertise operating room availability due to waiting lists) particularly when high complexity surgery is required to achieve complete cytoreduction. International disparities in access to surgical resources between high and low-middle income country settings also results in delays to surgery.\n\nKnowledge gap:\n\nThere is a paucity of data in the setting of extended use of neoadjuvant chemotherapy (more than four cycles). Data on the role of delayed cytoreduction surgery post four cycles are controversial. While some data have shown survival to be similar to that of patients undergoing interval cytoreductive surgery after three cycles,6-12 others have reported poorer prognosis. Conflicting data are due to selection biases such as heterogeneous inclusion criteria, small sample sizes and retrospective study designs. Delaying surgery to after four cycles has the potential to reduce surgical complexity and post-operative morbidity, and increase rates of complete cytoreduction (an independent marker of survival).\n\nOur multi-centre, international, retrospective cohort study (GO SOAR2) of 2498 women from twenty-two centres across twelve countries with advanced stage ovary cancer, showed that interval cytoreduction surgery was associated with statistically significant greater overall survival in comparison to delayed cytoreduction surgery (HR 0.81, p=0.01) but was associated with a higher GO SOAR surgical complexity score and greater surgical morbidity. Our results indicate that early maximum effort cytoreduction surgery with complete cytoreduction in high volume centres with appropriate surgical skill mix and resources, is what is needed to increase overall survival for women with advanced stage ovarian cancer.\n\nWe present the study design for a pragmatic phase III superiority randomised controlled trial comparing overall survival following interval and delayed cytoreductive surgery.\n\nOur hypothesis is that overall survival is greater following interval cytoreduction surgery when compared to delayed cytoreduction in women with stage III-IV epithelial ovarian cancer.",[27],[433],"surgery","2025-07-07",{"date":436,"type":34},"2025-07-16",{"date":438,"type":21},"2026-01-31",{"date":440,"type":21},"2034-01-31",{"name":442,"class":443},"NHS Grampian","OTHER_GOV",{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":454,"briefSummary":455,"conditions":456,"keywords":457,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":99},"100557639","phase-2-rc48-in-combination-with-ak104-and-bevacizumab-in-occc-100557639","NCT06540729","RC48 in Combination With AK104 and Bevacizumab in OCCC","Disitamab Vedotin (RC48) in Combination With AK104 (PD-1\u002FCTLA-4 Bispecific) and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer","DAB","Inclusion Criteria:\n\n* The pathological diagnosis confirms ovarian clear cell carcinoma. In cases of mixed carcinoma, a prerequisite is that clear cell carcinoma constitutes at least 70% of the tumor mass. Moreover, adherence to RECIST 1.1 criteria mandates the presence of at least one evaluable lesion.\n* HER2 IHC ≥1+.\n* Treatment-naïve individuals encompass those experiencing tumor progression during postoperative chemotherapy and those who, following platinum-containing neoadjuvant chemotherapy, have not undergone surgical intervention yet and subsequently manifested progression during or after platinum-containing chemotherapy, provided that they have received a maximum of 2 prior lines of chemotherapy.\n* Recurrent patients, whether platinum-sensitive or platinum-resistant, include those lacking a platinum-free interval of ≥6 months and who, post-recurrence, have undergone re-administration of platinum-containing chemotherapy but have demonstrated an inability to tolerate toxic reactions, with a maximum of 2 lines of chemotherapy post-recurrence.\n* Previous utilization of bevacizumab is permissible.\n* Adequate bone marrow reserve function necessitates pre-operative blood routine parameters meeting specific criteria: white blood cell count ≥3.0×10\\^9\u002FL, neutrophil count ≥1.5×10\\^9\u002FL, platelet count ≥100×10\\^9\u002FL, and hemoglobin ≥80 g\u002FL.\n* atisfactory organ function entails biochemical test results within defined limits: AST ≤2.5× upper limit of normal (ULN), ALT ≤2.5× ULN, serum total bilirubin ≤1.5× ULN, and creatinine ≤1.5× ULN.\n* ECOG performance status score ranging from 0 to 1.\n* Patient participation is contingent upon voluntary execution of an informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of immunotherapy, including treatments targeting PD-1, PD-L1, CAR-T, and CTLA-4.\n* Patients diagnosed with other malignancies within the past five years, excluding skin cancer and thyroid cancer.\n* Patients with an expected survival of ≤12 weeks.\n* Patients with a known allergy to taxane-based medications.\n* Patients who, based on clinical assessment, have contraindications for receiving immunotherapy and\u002For bevacizumab, such as uncontrolled infections, gastrointestinal fistula, autoimmune diseases, active hepatitis, or active bleeding.\n\nPatients currently undergoing treatment with investigational anti-cancer drugs in other clinical trials.\n\n* Patients with any unstable condition or situation that may compromise their safety or adherence to the study protocol.",{"count":453,"type":21},39,[24],"Disitamab vedotin (RC48) in combination with AK104 (PD-1\u002FCTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm, phase II, multicenter study (DAB OCC study)",[27],[458,459,460],"Disitamab vedotin","AK104","bevacizumab","2025-07-04",{"date":463,"type":34},"2025-07-08",{"date":465,"type":34},"2024-09-24",{"date":467,"type":21},"2030-08-01",{"name":469,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":99},"100541535","mesenteric-infiltration-in-ovarian-cancer-100541535","NCT06331130","Mesenteric Infiltration in Ovarian Cancer","CT Detected Tumour Infiltration Patterns of the Mesentery in High Grade Ovarian Carcinoma (HGSOC) Patients, Their Role in Treatment Planning and Outcome Prediction and How Machine Learning Can be Applied to Identify Them.","MIO","Inclusion Criteria:\n\n1. Women with confirmed HGSOC wiht mesenteric involvment\n2. Age \\> 18 years\n3. FIGO STAGE IIIB-IV\n4. Primary diagnosis\n5. Signed informed consent\n\nExclusion Criteria:\n\n1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer)\n2. Early stage disease (I and II stage)\n3. CT scan not available\n4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy",{"count":479,"type":21},510,"To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.",[27],"2025-03-11",{"date":484,"type":34},"2025-03-12",{"date":486,"type":34},"2024-03-01",{"date":488,"type":21},"2025-12-31",{"name":384,"class":41},{"id":491,"slug":492,"hasResults":11,"nctId":493,"briefTitle":494,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":99},"100577577","dysregulation-of-whole-body-metabolism-in-ovarian-cancer-a-longitudinal-study-100577577","NCT06800105","Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study","Inclusion Criteria:\n\n* Women\n* Age \\>18\n* Presumed ovarian cancer diagnosis (i.e. those being clinically evaluated for suspicion of ovary cancer)\n* Planned treatment course for ovarian cancer involving cytoreductive surgery followed by chemotherapy\n* Availability to commit to attending all study visits\n* Internet access and consistent access to phone\u002Femail\u002Ftext communication\n\nExclusion Criteria:\n\n* Pregnancy\n* Inability to provide voluntary informed consent\n* Inability to consume the pre-study visit meal\u002Fsnack and\u002For the study visit meal due to strict dietary restrictions\n* Illicit substance use (e.g. cocaine, methamphetamines, heroin, street drugs) - marijuana and CBD oil and related supplements will be considered on a case-by-case basis by the principal investigators\n* Circumstances and\u002For medical condition that would limit compliance with study requirements and protocol, as determined by the principal investigators",{"count":497,"type":21},10,"Minimal information is available regarding changes in whole-body metabolism in ovarian cancer patients, and no study has assessed whole-body lipid metabolism in this patient population. In this pilot study we will assess fasting and postprandial lipid metabolism of ovarian cancer patients before, during, and after treatment via indirect calorimetry.",[27],"2025-01-23",{"date":502,"type":34},"2025-01-29",{"date":504,"type":34},"2023-03-22",{"date":506,"type":21},"2028-03-31",{"name":508,"class":41},"University of Tennessee Graduate School of Medicine",{"id":510,"slug":511,"hasResults":11,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":99},"100558839","the-efficacy-and-safety-of-frd001-in-ultrasound-contrast-imaging-for-malignant-ovarian-masses-in-women-100558839","NCT06556342","The Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in Women","Efficacy and Safety of FRD001 Injection in Ultrasound Contrast Imaging for the Differential Diagnosis of Benign and Malignant Ovarian Masses in Women","Inclusion Criteria:\n\nAll participants must meet the following inclusion criteria to be eligible for enrollment in this study:\n\n* Female participants aged 18 to 75 years (inclusive of the age limits);\n* Patients with untreated unilateral or bilateral, unilocular or multilocular cystic\u002Fsolid masses;\n* Expected survival of at least 3 months;\n* ECOG performance status of 0 to 2 for participants with malignant tumors;\n* Organ function levels must meet the following requirements: a. Hematology: WBC ≥ 3 × 10\\^9\u002FL, ANC ≥ 1.5 × 10\\^9\u002FL, Hb ≥ 90 g\u002FL, PLT ≥ 75 × 10\\^9\u002FL; b. Liver function: TBIL ≤ 1.5 × ULN, ALT and AST ≤ 3 × ULN (≤ 5 × ULN for patients with liver metastases); c. Kidney function: Cr ≤ 1.5 × ULN; d. Coagulation function: Prothrombin time (PT) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN, International normalized ratio (INR) ≤ 1.5 × ULN; e. Electrolytes: Corrected magnesium ≥ LLN, with allowance for correction of electrolytes during screening; f. Cardiac function: Left ventricular ejection fraction ≥ 50%; g. Pulse oximetry ≥ 93%;\n* Women of childbearing potential must use effective contraception during the study (effective contraceptive methods include sterilization, intrauterine hormonal devices, condoms, contraceptive pills\u002Fdevices, abstinence, or vasectomy);\n* Participants must fully understand the purpose, nature, methods, and potential adverse reactions of the trial, voluntarily agree to participate, and sign a written informed consent form, demonstrating the ability to adhere to the protocol requirements to complete the study.\n\nExclusion Criteria:\n\nParticipants who meet any of the following criteria are not eligible for enrollment:\n\n* Patients with benign teratomas;\n* Patients who have undergone total removal of the uterine appendages;\n* Patients with congenital malformations of the reproductive system;\n* Patients who have received radiotherapy, chemotherapy, or invasive procedures (including but not limited to radiofrequency ablation) during the administration of the investigational medicinal product (IMP) and the confirmatory diagnostic examination;\n* Women planning to become pregnant within 6 months, currently pregnant, or breastfeeding, or women of childbearing potential with a positive pregnancy test during the screening period;\n* Individuals allergic to the components of FRD001 injection or with a history of other severe allergies;\n* Insufficient acoustic window indicated by ultrasound examination during screening or prior examinations;\n* Presence of contraindications for imaging examinations related to the study protocol;\n* Conditions such as adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or pulmonary embolism;\n* Severe cardiovascular or cerebrovascular diseases, including but not limited to: a. Significant cardiac rhythm or conduction abnormalities that require clinical intervention, such as ventricular arrhythmias, second- to third-degree atrioventricular block, or QTc interval ≥ 450 ms; b. Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, or other cardiovascular events of grade 3 or higher within 6 months prior to the first dose; c. New York Heart Association (NYHA) functional classification ≥ II or left ventricular ejection fraction (LVEF) \\\u003C 50%;\n* Known severe pulmonary hypertension or uncontrolled systemic hypertension; uncontrolled hypertension (for individuals \\\u003C60 years old, systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg; for individuals ≥ 60 years old, systolic blood pressure ≥ 150 mmHg and diastolic blood pressure ≥ 90 mmHg);\n* Patients with symptomatic brain metastases requiring treatment;\n* Individuals with severe or uncontrolled mental illness;\n* Presence of active infections requiring systemic treatment or uncontrolled infections within 14 days prior to starting the investigational drug;\n* Positive tests for antibodies to human immunodeficiency virus (HIV), hepatitis C virus (HCV), or Treponema pallidum; positive hepatitis B virus (HBV) surface antigen;\n* History of right-to-left, bidirectional, or transient right-to-left cardiac shunts;\n* History of alcohol or drug abuse\u002Fdependence;\n* Participation in other clinical trials involving investigational drugs within 30 days prior to screening;\n* Any medications or treatments deemed by the investigator to potentially interfere with trial data or cause severe side effects that have not been fully washed out prior to enrollment;\n* Any other conditions deemed inappropriate for participation in this clinical trial by the investigator.",{"count":517,"type":21},198,[54],"This is a Prospective, Self-Controlled, Open-Label, Multicenter Clinical Trial. The purpose of this study is to demonstrate the efficacy and safety of FRD001 injection in ultrasound contrast imaging for the differentiation between benign and malignant ovarian masses in women, using gray-scale and power Doppler ultrasound as controls. This trial will adopt a self-controlled design, where each participant will first undergo gray-scale\u002Fpower Doppler ultrasound imaging, followed by FRD001 injection-enhanced ultrasound imaging. The target population is assumed to have a malignancy prevalence (P) of 40%, with an expected sensitivity of gray-scale\u002Fpower Doppler ultrasound at 70%. It is hypothesized that the sensitivity of FRD001 injection-enhanced ultrasound will improve by 20%, reaching an anticipated sensitivity of 90%. The significance level (α) is set at 0.05, with a power (1-β) of 80%, and an inconsistency ratio (D) of 0.34. Based on these parameters, a total sample size (N) of 178 cases is required. Considering a 10% dropout rate, at least 198 subjects will be needed, which includes 79 participants with malignant tumors (N1) and 119 with benign conditions (N2). All screening assessments for each participant will be conducted within 7 days prior to the administration of the investigational medicinal product (IMP), including the day of administration. Safety observations will continue for 72 ± 24 hours post-IMP administration. Pathological results for the target lesions will be collected within 30 days following the IMP imaging examination. The efficacy of the IMP in differentiating between benign and malignant ovarian masses will be evaluated against pathological results, which will serve as the gold standard. This comprehensive approach will provide crucial insights into the diagnostic capabilities of FRD001 injection, potentially enhancing clinical decision-making in the management of ovarian masses.",[27],"2024-08-13",{"date":523,"type":34},"2024-08-16",{"date":525,"type":34},"2024-07-01",{"date":527,"type":21},"2028-07-01",{"name":529,"class":41},"Tongji Hospital",{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":11,"sex":50,"minAge":17,"maxAge":392,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":546,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":99},"100453653","phase-1-triplex-checkpoint-inhibitors-therapy-for-advanced-solid-tumors-100453653","NCT05187338","Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","Triplex CTLA4\u002FPD1\u002FPDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors","Inclusion Criteria:\n\n1. Cytohistological confirmation is required for diagnosis of cancer.\n2. Signed informed consent before recruiting.\n3. Age above 18 years with estimated survival over 3 months.\n4. Child-Pugh class A or B\u002FChild score \\> 7; ECOG score \\\u003C 2\n5. Tolerable coagulation function or reversible coagulation disorders\n6. Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9\u002FL; Hb≥90g\u002FL； PLT ≥50×10E9\u002FL；INR \\\u003C 2.3 or PT \\\u003C 6 seconds above control；Cr ≤ 145.5 umul\u002FL；Albumin \\> 28 g\u002FL；Total bilirubin \\\u003C 51 μmol\u002FL\n7. At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1.\n8. Birth control.\n9. Willing and able to comply with scheduled visits, treatment plan and laboratory tests.\n\nExclusion Criteria:\n\n1. Patients participated in clinical trials of equipment or drugs (signed informed consent) within 4 weeks;\n2. Patients accompany by ascites, hepatic encephalopathy and esophageal and gastric varices bleeding;\n3. Any serious accompanying disease, which is expected to have an unknown, impact on the prognosis, include heart disease, inadequately controlled diabetes and psychiatric disorders;\n4. Patients accompanied with other tumors or past medical history of malignancy;\n5. Pregnant or lactating patients, all patients participating in this trial must adopt appropriate birth control measures during treatment;\n6. Patients have poor compliance.\n\n   Any contraindications for hepatic arterial infusion procedure:\n\n   A.Impaired clotting test (platelet count \\\u003C 60000\u002Fmm3, prothrombin activity \\\u003C 50%).\n\n   B.Renal failure \u002F insufficiency requiring hemo-or peritoneal dialysis. C.Known severe atheromatosis. D.Known uncontrolled blood hypertension (\\> 160\u002F100 mm\u002FHg).\n7. Allergic to contrast agent;\n8. Any agents which could affect the absorption or pharmacokinetics of the study drugs\n9. Other conditions that investigator decides not suitable for the trial.",{"count":538,"type":21},100,[111,24],"This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or intra-tumor (IT).",[130,542,115,59,27,173,57,543,213,544,545],"Liver Cancer","Gastric Cancer","Esophageal Cancer","Sarcoma",[547,548,549,550,551,552,553],"Solid tumor","CTLA4 antibody","PD1 antibody","PDL1 antibody","Interventional Radiology","Trans-artery infusion","Intra-tumor injection","2024-06-23",{"date":556,"type":34},"2024-06-25",{"date":558,"type":34},"2021-11-01",{"date":560,"type":21},"2035-10-30",{"name":562,"class":41},"Second Affiliated Hospital of Guangzhou Medical University",{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":99},"100497919","improved-diagnosis-of-ovarian-cancer-by-use-of-circulating-tumor-dna-as-a-biomarker-100497919","NCT05763511","Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker","Inclusion Criteria:\n\n* Suspected ovarian neoplasm\n* Informed consent\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Previous ovarian cancer diagnosis",{"count":570,"type":21},300,"This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy.\n\nWe hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses.\n\nSpecifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm.\n\nThe mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored.\n\nAnalyses of blood and tissue samples will be used to examine the disease development and biology.\n\nBlood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.",[127,27,573],"Ovarian Cysts","2024-05-08",{"date":576,"type":34},"2024-05-09",{"date":578,"type":34},"2022-07-01",{"date":580,"type":21},"2029-05-04",{"name":582,"class":41},"University of Aarhus",{"id":584,"slug":585,"hasResults":11,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":589,"eligibilityCriteria":590,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":599,"lastUpdatePostDateStruct":600,"startDateStruct":602,"completionDateStruct":604,"leadSponsor":606,"locationsCount":99},"100445447","phase-2-adaptive-chemotherapy-for-ovarian-cancer-in-patients-with-replased-platinum-sensitive-high-grade-serous-or-high-grade-endometrioid-ovarian-cancer-100445447","NCT05080556","Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","A Multicentre Phase II Randomised Controlled Trial to Evaluate the Efficacy of Adaptive Therapy (AT) With Carboplatin, Based on Changes in CA125, in Patients With Relapsed Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer","ACTOv","Inclusion Criteria:\n\n1. Female patients aged ≥18 years\n2. ECOG performance status 0-2\n3. Histologically proven diagnosis of high grade serous or high grade endometrioid carcinoma of the ovary, fallopian tube or peritoneum\n4. Most recent regimen must have included platinum (cisplatin or carboplatin)\n5. Must have previously received a PARP inhibitor\n6. 6\\. Must have responded to most recent platinum treatment by CT or MRI or by GCIG CA125 response criteria\n7. Pre-trial CT or MRI-confirmed disease relapse ≥ 6 months after day 1 of the last cycle of platinum-containing chemotherapy (cisplatin or carboplatin) and requiring treatment with further platinum-based chemotherapy\n8. Measurable disease by RECIST v1.1 on a CT scan conducted within 28 days prior to randomisation (Patient with non-measurable disease could be eligible if they meet GCIG CA125 progression criteria)\n9. CA125 ≥ 100iU\u002Fl at screening\n10. Agree to provide additional research blood samples at the same time as blood draws prior to each carboplatin treatment, 6-weekly during surveillance and at 12- weekly follow-up visit\n11. Expected to be able to commence treatment within 28 days post randomisation\n12. Adequate bone marrow function\n13. Adequate liver function\n14. Adequate renal function\n15. Postmenopausal or women of child-bearing potential (WOCBP) must agree to have an urine or serum pregnancy test at screening for evidence of non-childbearing status and prior to trial treatment and use adequate contraception for duration of trial\n16. Willing and able to give consent and able to comply with treatment and follow up schedule\n\nExclusion Criteria:\n\n1. Non-epithelial ovarian cancer, carcinosarcoma, low-grade serous and endometrioid carcinomas, mucinous \\& clear-cell carcinomas\n2. Patients requiring treatment with combination chemotherapy regimens\n3. Patients with a known hypersensitivity to carboplatin\n4. Persisting ≥ grade 2 CTCAE v5 adverse events\u002F toxicity (except alopecia and neuropathy) from previous anti-cancer treatment.\n5. Treatment with any other investigational agent, or participation in another interventional clinical trial within 28 days prior to randomisation.\n6. Major surgery within 14 days before anticipated start of treatment and patients must have recovered from any effects of major surgery.\n7. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contra-indicated the use of an investigation drug or puts the patients at high risk for treatment-related complications.\n8. Other psychological, psychiatric, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results.\n9. Malignancy treated within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, Stage 1, grade 1 endometrial carcinoma.\n10. Patients with symptomatic uncontrolled brain or meningeal metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.\n11. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days prior to randomisation.\n12. Pregnant or breast-feeding women are excluded. Women of childbearing potential will be excluded unless effective methods of contraception are used from signing of the informed consent, throughout the period of taking study treatment and for at least 6 months after last dose of trial drug(s).\n13. Inability to attend or comply with treatment or follow-up scheduling.",{"count":592,"type":21},80,[24],"ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.",[126,596,29,28,597,598,27],"Relapsed Ovarian Cancer","Endometrioid Carcinoma","High Grade Serous Carcinoma","2024-04-11",{"date":601,"type":34},"2024-04-12",{"date":603,"type":34},"2023-05-24",{"date":605,"type":21},"2027-11-01",{"name":607,"class":41},"University College, London",{"id":609,"slug":610,"hasResults":11,"nctId":611,"briefTitle":612,"officialTitle":612,"acronym":613,"eligibilityCriteria":614,"healthyVolunteers":11,"sex":16,"minAge":615,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":168,"phases":4,"briefSummary":618,"conditions":619,"keywords":624,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":634,"locationsCount":4},"100541396","serum-and-plasma-micrornas-in-malignant-ovarian-germ-cell-tumours-100541396","NCT06329323","SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours","SUMMER","Inclusion Criteria:\n\n* All patients with a new diagnosis of a malignant ovarian germ cell tumour.\n* The control population will include all patients with a new diagnosis of a benign ovarian germ cell tumour or no known gynaecological pathology.\n\nExclusion Criteria:\n\n* Previous or ongoing chemotherapy for MOGCT\n* Previous surgery for MOGCT\n* Pregnancy - this will be verbally communicated for those not having surgery or chemotherapy, for those having surgery or chemotherapy a urine pregnancy test should be negative and documented in the clinical notes.\n* Fetal circulating DNA is known to be present in maternal blood and therefore pregnant women should not be included in this study\n* Denial of informed consent\n* Age \\\u003C16 years\n* History of any other cancer","16 Years",{"count":617,"type":21},24,"The goal of this observational case-control study is to learn about the circulating and tissue microRNA expression, imaging and radiomic profiles of malignant ovarian germ cell tumours (MOGCT) compared to patients with a benign OGCT and no ovarian pathology.\n\nThe main question\\[s\\] it aims to answer are:\n\n1. To understand the circulating miRNA expression of malignant ovarian germ cell tumours (MOGCTs) compared to those with benign ovarian germ cell tumours (BOGCTs)\n2. To understand the imaging profile of MOGCTs compared to that of BOGCTs\n3. To establish the relationship between serum and plasma miRNA expression in response to treatment and relapse of disease\n4. To discover if miRNA expression correlates with radiomic features of OGCTs on both ultrasound and MRI\n5. To see if we can link the micro RNAs in tumour samples to those found in blood samples, and to find a plausible explanation for why these micro RNAs are raised (in terms of the tumour biology itself).aims\n\nParticipants will have serial blood tests at different time points in their care to assess how circulating miRNA levels are affected by treatment and\u002For remission and\u002For relapse. If they have surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their mass.\n\nResearchers will compare the circulating miRNA profile of patients with a benign ovarian germ cell tumour and no ovarian pathology to see where the differences lie. If a patient with a BOGCT requires surgery, a pathology sample will be taken from the main tumour specimen. Radiomic analysis will take place on existing ultrasound images of their benign mass.",[620,621,622,623,27,302,126,127],"Germ Cell Ovarian Cancer","Germ Cell Tumor","Germ Cell Cancer","Germ Cell Neoplasia",[622,625,626,126],"microRNA","miRNA","2024-03-25",{"date":629,"type":34},"2024-03-26",{"date":631,"type":21},"2024-04-14",{"date":633,"type":21},"2028-04",{"name":635,"class":41},"Imperial College London"]